Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Moodys
Harvard Business School
Merck
McKinsey
Dow

Last Updated: December 15, 2019

DrugPatentWatch Database Preview

Alpharma Company Profile

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

Summary for Alpharma
International Patents:54
US Patents:9
Tradenames:45
Ingredients:42
NDAs:63
Patent Litigation for Alpharma: See patent lawsuits for Alpharma

Drugs and US Patents for Alpharma

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Alpharma Us Pharms THIORIDAZINE HYDROCHLORIDE thioridazine hydrochloride CONCENTRATE;ORAL 087766-001 Apr 26, 1983 DISCN No No   Start Trial   Start Trial
Alpharma Us Pharms SERAX oxazepam CAPSULE;ORAL 015539-004 Approved Prior to Jan 1, 1982 DISCN No No   Start Trial   Start Trial
Alpharma Us Pharms PROMETH FORTIS promethazine hydrochloride SYRUP;ORAL 084772-001 Approved Prior to Jan 1, 1982 DISCN No No   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for Alpharma

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Alpharma Pharms EMBEDA morphine sulfate; naltrexone hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 022321-002 Aug 13, 2009 5,202,128   Start Trial
Alpharma Us Pharms SERAX oxazepam CAPSULE;ORAL 015539-006 Approved Prior to Jan 1, 1982 4,620,974   Start Trial
Alpharma Us Pharms SERAX oxazepam CAPSULE;ORAL 015539-002 Approved Prior to Jan 1, 1982 4,620,974   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration
Paragraph IV (Patent) Challenges for ALPHARMA drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Extended-release Capsules 60 mg/2.4 mg ➤ Subscribe 2010-05-25
➤ Subscribe Extended-release Capsules 30 mg/1.2 mg, 50 mg/2 mg and 80 mg/3.2 mg ➤ Subscribe 2010-05-28
➤ Subscribe Extended-release Capsules 100 mg/4 mg ➤ Subscribe 2010-05-03

Supplementary Protection Certificates for Alpharma Drugs

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0809498 10C0038 France   Start Trial PRODUCT NAME: ACYCLOVIR ET HYDROCORTISONE; NAT. REGISTRATION NO/DATE: NL 36 826 20100420; FIRST REGISTRATION: SK - 2108/08467-R 20091026
0428296 SPC/GB98/013 United Kingdom   Start Trial PRODUCT NAME: LOPERAMIDE HYDROCHLORIDE AND SIMETHICONE; REGISTERED: UK 00242/0314 19970923
1429780 SPC/GB12/058 United Kingdom   Start Trial PRODUCT NAME: A COMBINATION OF CIPROFLOXACIN AND DEXAMETHASONE, PREFERABLY CIPROFLOXACIN HYDROCHLORIDE AND DEXAMETHASONE; REGISTERED: DK DE/11/3337/001/DC 20120808; UK PL000649/0381-0001 20121003
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
McKinsey
Baxter
McKesson
Boehringer Ingelheim
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.